The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.

@article{Noseworthy1994TheIO,
  title={The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.},
  author={John H. Noseworthy and George Cornell Ebers and Margaret K. Vandervoort and R E Farquhar and Elizabeth Yetisir and Richard Roberts},
  journal={Neurology},
  year={1994},
  volume={44 1},
  pages={16-20}
}
In the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: i.v. cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to placebo (group III: sham plasma exchange and placebo medications) using the blinded, evaluating neurologists' assessments of disease course (primary analysis). All patients were examined by both a… CONTINUE READING